Agarwal, R (2009). Allergic bronchopulmonary aspergillosis. Chest. 135: 805-826.
Asher, MI; Montefort, S; Björkstén, B; Lai, CK; Strachan, DP; Weiland, SK; Williams, H and ISAAC Phase Three Study Group (2006). Worldwide time trends in the prevalence of symptoms of asthma, allergic rhino-conjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 368: 733-743.
Bateman, ED; Hurd, SS and Barnes, PJ (2008). Global strategy for asthma management and prevention: GINA executive summary. Europ. Resp. J., 31: 143-178.
Berlin, C; Kowalewski, DJ; Schuster, H; Mirza, N; Walz, S; Handel, M; Schmid-Horch, B; Salih, HR; Kanz, L; Rammensee, HG; Stevanovic, S and Stickel, JS (2014). Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia, 30: 1003-1004.
Douglas, G; Higgins, B and Barnes, N (2008). British guideline on the management of asthma: a national clinical guideline. Thorax. 63: iv1-iv121.
Hafner, R; Couroux, P; Armstrong, K; Patel, D; Larche, M and Haumann, B (2013). Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immune-regulatory epitopes. Clin. Transl. Allergy. S3: O7.
Immonen, A; Farci, S; Taivainen, A; Partanen, J; Pouvelle-Moratille, S; Narvanen, A; Kinnunen, T; Saarelainen, S; Rytkonen-Nissinen, M; Maillere, B and Virtanen, T (2005). T cell epitope-containing peptide of the major dog allergen Can f 1 as candidates for allergen immunotherapy. J. Immunol., 175: 3614-3620.
Lowe, L; Custovic, A and Woodcock, A (2004). Childhood asthma. Curr. Allergy Asthm. R., 4: 159-165.
Moldaver, D and Larche, M (2011). Immunotherapy with peptides. Allergy. 66: 784-791.
National Asthma Education and Prevention Program (2007). Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J. Allergy Clin. Immunol., 120: S94-S138.
Nielsen, M and Lund, O (2009). NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 10: 296-
Nielsen, M; Lundegaard, C and Lund, O (2007). Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics. 8: 238-250.
Oseroff, C; Sidney, J; Vita, R; Tripple, V; McKinney, DM; Southwood, S; Brodie, TM; Sallusto, F; Grey, H; Alam, R; Brodie, D; Greenbaum, JA; Kolla, R; Peters, B and Sette, A (2012). T cell responses to known allergen proteins are differently polarized and account for a variable fraction of total response to allergen extracts. J. Immunol., 189: 1800-1811.
Park, H; Ahn, K; Park, MH and Lee, SI (2012). The HLA-DRB1 polymorphism is associated with atopic dermatitis, but not egg allergy in Korean children. Allergy Asthma Immunol. Res., 4: 143-149.
Prescott, SL and Tang, MLK (2005). The Australasian Society of Clinical Immunology and Allergy position statement: summary of allergy prevention in children. Med. J. Aust., 182: 464-467.
Prickett, SR; Voskamp, AL; Phan, T; Dacumos-Hill, A; Mannering, SI; Rolland, JM and O’Hehir, RE (2013). Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic. Clin. Exp. Allergy. 43: 684-697. doi: 10.1111/cea.12113.
Sirskyj, D; Diaz-Mitoma, F; Golshani, A; Kumar, A and Azizi, A (2011). Innovative bioinformatics approaches for developing peptide based vaccines against hypervariable viruses. Immunol. Cell Biol., 89: 81-89.
Sonpavde, G; Wang, M; Peterson, LE; Wang, HY; Joe, T; Mims, MP; Kadmon, D; Ittmann, MM; Wheeler, TM; Gee, AP; Wang, RF and Hayes, TG (2014). HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest. New Drugs. 32: 235-242. doi: 10.1007/s10637-013-9960-9.
TePas, EC; Litonjua, AA; Celedón, JC; Sredl, D and Gold, DR (2006). Sensitization to aeroallergens and airway hyper responsiveness at 7 years of age. Chest. 129: 1500-1508.
Tipu, HN and Ahmed, D (2014). Differential binding of Aspergillus fumigatus allergenic proteins to human leuko-cyte antigen (HLA) alleles in dry lab: potential for immunotherapy. Cell. Biol.: Res. Ther., 3(1). doi: 10.4172/ 2324-9293.1000111.
Tipu, HN; Ahmed, TA and Bashir, MM (2011). Human leukocyte antigen class II susceptibility conferring alleles among non-insulin dependent diabetes mellitus patients. J. Coll. Physicians Surg. Pak., 21: 26-29.
Tipu, HN; Babar, ME and Hussain, T (2014). Binding affinities of dengue virus envelope glycoprotein residues with human leukocyte antigen alleles: dry lab candidates for synthetic vaccines. Life Sci. J., 11: 552-557.
Tomar, N and De, RK (2010). Immunoinformatics: an integrated scenario. Immunology. 131: 153-168.
Wand, P; Sidney, J; Kim, Y; Sette, A; Lund, O and Nielsen, M (2010). Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 11: 568-580.
Whelan, FJ; Yap, NVL; Surette, MG; Golding, GB and Bowdish, DME (2013). A guide to bioinformatics for immunologists. Front. Immunol., 4: 1-16.
Worm, M; Lee, HH; Kleine-Tebbe, J; Hafner, RP; Laidler, P; Healey, D; Buhot, C; Verheof, A; Maillere, B; Kay, AB and Larche, M (2011). Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J. Allergy Clin. Immunol., 127: 89-97.